Clinical relevance
Addresses retained blood syndrome through physiologic, temperature-controlled flushing
Every beat matters
Every beat
matters.
Every heartbeat carries a life full of moments. When heart surgery is needed, recovery is the next vital chapter. Osalina is developing a flushing device designed to support recovery after heart surgery.
Demonstrated impact
Associated with 40% fewer pericardial reinterventions in a pooled analysis presented at EACTS 20241
Simply elegant solution
Combines flushing, drainage, and monitoring in one device. Designed to support icu staff.
A NEED AFFECTING MILLIONS
When surgery ends,
recovery begins.
Every year, more than a million open-heart cardiac surgeries help people move toward a healthier future. Yet the hours after surgery remain a critical part of the patient's journey.
Blood can remain around the heart after surgery. If drainage is inadequate, clots may block the tubes and lead to further complications. The work of recovery continues beyond the operating theatre.
The clinical insight →+1Mcardiac surgical procedures estimated worldwide each year
36%of patients had at least one completely clogged chest tube in one study
Post-operative drainage is a small part of the operation but it is a vital part of recovery.
Global volume estimate, 2024 · Karimov et al., 2013Retained blood syndrome (RBS) affects approximately one in five patients after cardiac surgery. Blood left around the heart or lungs can impair their function within hours and trigger inflammation lasting weeks to months. Persistent inflammation may lead to scarring that restricts heart function or lung expansion. Associated with further procedures and longer hospital stays, RBS makes effective blood drainage an important priority in postoperative care.Niemann and Grieshaber, 2025
A NEED ROOTED IN CLINICAL PRACTICE
Strong clinical relevance
Solving a real
clinical problem.
As a cardiac surgeon, Dr. Dave R Koolbergen saw how much care goes into a successful operation—and how vulnerable the hours after it can be. That clinical question became the starting point for continuous postoperative pericardial flushing.
“There is no successful heart surgery without successful post-operative care.”
FROM CLINICAL NEEDS TO INNOVATION
The development
From design
to clinical testing.
Supported by 11 years of clinical history established through a robust development phase. Our therapy builds on academic proof-of-concept research at Amsterdam UMC, followed by two randomized controlled trials (RCTs) that provided further clinical evidence. The study with the prototype demonstrated efficacy on reduction of blood loss in a multicenter RCT and informed the development of our patented technology for automating the procedure. Pooled data from the academic research and prototype studies provided evidence supporting safety and efficacy, alongside technological proof of concept to guide development of a fully automated solution.
Our solution
Continuous flushing.
Designed around recovery.
Osalina is developing an automated system providing continuous postoperative pericardial flushing with drain output monitoring.
Explore the therapy
Device under development. Not CE marked or FDA cleared or approved. For information only; not available for sale.
Clinical research
Evidence for the approach.
Product validation is next.
Three randomized trials have studied continuous postoperative pericardial flushing, with pooled data from 744 patients. These findings relate to the therapeutic approach, not the Osalina system; product validation and regulatory review remain ahead.
REINTERVENTIONS
−40%Reduction in pericardial reinterventions in a pooled analysis
p = 0.044POOLED DATA
744Patients included in the pooled clinical analysis
RANDOMIZED TRIALS
3Randomized trials have studied the CPPF approach
Additional confirmatory study planned
THE TEAM BEHIND THE INNOVATION
Our team
Complementary expertise.
Practical innovation.
Our team combines complementary healthcare knowledge with expertise in engineering, quality and commercialization to translate clinical needs into practical innovations for medical teams.
Arash Dodge
Chief Executive Officer
Andrea Fiorenzi
Chief Operating Officer
Maarten Haast
Chief Financial Officer
Katarzyna Feliksik
Quality & Regulatory Affairs Director
Samuela Loosli
Marketing Lead
Lian van Lippen
Clinical Trial Lead
Pleuni Lodiers
Biomedical Engineer
Our advisory panel
Our strategic direction is further refined by a diverse Advisory Panel that provides a 360-degree view of the cardiac surgery ecosystem. Their combined wisdom ensures us to address the specific clinical and economic needs of surgeons, intensive care units, hospital administrations, and payers alike.
PARTNERS BRINGING IT FORWARD
A connected ecosystem
Strong partnerships.
Built together.
Clinical, research, technology and innovation partners contribute to the work behind Osalina.
Osalina Medical
Every beat matters.
Every recovery matters.
We are bringing our first product toward its next clinical and regulatory milestones. Connect with us to follow the journey or explore a partnership.
Email us